United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attributed the shortfall mainly to seasonality and operational disruptions, including severe winter weather and pharmacy issues that slowed patient starts early in the quarter. CEO Dr. Martine Rothblatt emphasized continued progress in the development pipeline, highlighting successful Phase III trial results for both ralinepag and Tyvaso in major indications. President Michael Benkowitz noted that demand for Tyvaso DPI remains robust, with increased patient referrals and shipments in recent months.

Is now the time to buy UTHR? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From United Therapeutics’s Q1 Earnings Call

• Ashwani Verma (UBS) asked about the regulatory path for Tyvaso DPI in IPF and how it will compete with new drugs like JASCAYD; EVP Leigh Peterson confirmed ongoing FDA discussions on bridging studies and noted strong physician interest in Tyvaso based on trial data.
• Roanna Clarissa Ruiz (Leerink Partners) questioned how the commercial strategy and peak sales expectations are evolving given the expanding product portfolio; President Michael Benkowitz explained that detailed forecasts will be shared as market feedback is collected, but management anticipates more than doubling revenue in the coming years.
• Jessica Fye (JPMorgan) inquired about the new ralinepag DPI product and its development timeline; EVP Patrick Poisson said Phase I studies are targeted for completion by year-end, with rapid advancement expected due to the molecule’s properties and existing regulatory engagement.
• Olivia Brayer (Cantor) sought clarity on which IPF formulations are likely to succeed and how different drug-device combinations will be prioritized; Benkowitz emphasized a patient-tailored approach, developing multiple options to address diverse clinical needs, while Peterson detailed regulatory considerations for each.
• Roger Song (Jefferies) asked about the upcoming PH-COPD program and product sequencing; Peterson outlined the plan to begin Phase II studies later this year using treprostinil SMI, following learnings from prior PAH and PH-ILD programs.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely monitor (1) the pace and success of Tyvaso and ralinepag regulatory filings and approvals, (2) execution of product launches into new indications and associated commercial uptake, and (3) progress in developing and scaling new formulations such as RALDPI. Additional signals of execution will include adoption trends among prescribers and payer coverage decisions.

United Therapeutics currently trades at $569.00, in line with $572.20 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.